Literature DB >> 18845769

Simultaneous measurement of plasma concentrations of proinsulin and C-peptide and their ratio with a trefoil-type time-resolved fluorescence immunoassay.

Pieter E M De Pauw1, Ilse Vermeulen, Ogonnaya C Ubani, Inge Truyen, Evilien M F Vekens, Farah T van Genderen, Joeri W De Grijse, Daniel G Pipeleers, Chris Van Schravendijk, Frans K Gorus.   

Abstract

BACKGROUND: When the concentrations of 2 or more substances are measured separately, their molar ratios are subject to the additive imprecisions of the different assays. We hypothesized that the cumulative error for concentration ratios of peptides containing a common sequence might be minimized by measuring the peptides simultaneously with a "trefoil-type" immunoassay.
METHODS: As a model of this approach, we developed a dual-label time-resolved fluorescence immunoassay (TRFIA) to simultaneously measure proinsulin, C-peptide, and the proinsulin-C-peptide ratio (PI/C). A monoclonal antibody captures all C-peptide-containing molecules, and 2 differently labeled antibodies distinguish between proinsulin-like molecules and true C-peptide.
RESULTS: The trefoil-type TRFIA was capable of measuring plasma C-peptide and proinsulin simultaneously without mutual interference at limits of quantification of 48 and 8125 pmol/L, and 2.1 and 197 pmol/L, respectively. Within-laboratory imprecision values for the trefoil-type TRFIA ranged between 8.4% and 12% for the hormone concentrations. Unlike the hormone results obtained with separate assays, imprecision did not increase when PI/C was calculated from trefoil assay results (P < 0.05). Peptide concentrations were highly correlated with results obtained in individual comparison assays (r(2) > or = 0.965; P < 0.0001). The total error for PI/C obtained with the trefoil-type TRFIA remained < or = 25% over a broader C-peptide range than with separate hormone assays (79-7200 pmol/L vs 590-4300 pmol/L C-peptide). Preliminary data indicate little or no interference by heterophile antibodies.
CONCLUSIONS: The developed trefoil-type TRFIA is a reliable method for simultaneous measurement of proinsulin, C-peptide, and PI/C and provides proof of principle for the development of other trefoil-type multiple-label immunoassays.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845769     DOI: 10.1373/clinchem.2008.109710

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

1.  Detection of anticardiolipin antibody IgG by time-resolved fluoroimmunoassay.

Authors:  Yan Ye; Zhigang Hu; Jie Liu; Guoqian Chen; Yaohong Zhou; Lei Yu
Journal:  Clin Rheumatol       Date:  2012-06-10       Impact factor: 2.980

2.  A magnetic nanoparticle-based time-resolved fluoroimmunoassay for determination of the cytokeratin 19 fragment in human serum.

Authors:  Guanfeng Lin; Tiancai Liu; Jingyuan Hou; Zhiqi Ren; Jianwei Zhou; Qianni Liang; Zhenhua Chen; Wenqi Dong; Yingsong Wu
Journal:  J Fluoresc       Date:  2015-02-10       Impact factor: 2.217

3.  Detection of Hepatitis B Virus Large Surface Protein Using a Time-Resolved Immunofluorometric Assay.

Authors:  Zhigang Hu; Mei Li; Jie Liu; Lei Yu; Yifeng Xue; Yu Chen
Journal:  J Clin Lab Anal       Date:  2014-10-02       Impact factor: 2.352

4.  Eu3+ /Sm3+ dual-label time-resolved fluoroimmunoassay for measurement of hepatitis C virus antibodies.

Authors:  Xue Yang; Yan Ye; Tingting Wang; Mei Li; Lei Yu; Min Xia; Jun Qian; Zhigang Hu
Journal:  J Clin Lab Anal       Date:  2018-08-26       Impact factor: 2.352

5.  SLC30A8 polymorphism and BMI complement HLA-A*24 as risk factors for poor graft function in islet allograft recipients.

Authors:  Else M Balke; Simke Demeester; DaHae Lee; Pieter Gillard; Robert Hilbrands; Ursule Van de Velde; Bart J Van der Auwera; Zhidong Ling; Bart O Roep; Daniël G Pipeleers; Bart Keymeulen; Frans K Gorus
Journal:  Diabetologia       Date:  2018-04-20       Impact factor: 10.122

6.  A composite immune signature parallels disease progression across T1D subjects.

Authors:  Cate Speake; Samuel O Skinner; Dror Berel; Elizabeth Whalen; Matthew J Dufort; William Chad Young; Jared M Odegard; Anne M Pesenacker; Frans K Gorus; Eddie A James; Megan K Levings; Peter S Linsley; Eitan M Akirav; Alberto Pugliese; Martin J Hessner; Gerald T Nepom; Raphael Gottardo; S Alice Long
Journal:  JCI Insight       Date:  2019-12-05

7.  Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.

Authors:  Annelien Van Dalem; Simke Demeester; Eric V Balti; Bart Keymeulen; Pieter Gillard; Bruno Lapauw; Christophe De Block; Pascale Abrams; Eric Weber; Ilse Vermeulen; Pieter De Pauw; Daniël Pipeleers; Ilse Weets; Frans K Gorus
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

8.  Functional Beta Cell Mass from Device-Encapsulated hESC-Derived Pancreatic Endoderm Achieving Metabolic Control.

Authors:  Thomas Robert; Ines De Mesmaeker; Geert M Stangé; Krista G Suenens; Zhidong Ling; Evert J Kroon; Daniel G Pipeleers
Journal:  Stem Cell Reports       Date:  2018-03-01       Impact factor: 7.765

9.  Cell Mass Increase Associated with Formation of Glucose-Controlling β-Cell Mass in Device-Encapsulated Implants of hiPS-Derived Pancreatic Endoderm.

Authors:  Thomas Robert; Ines De Mesmaeker; Freya O Van Hulle; Krista G Suenens; Geert M Stangé; Zhidong Ling; Corinne Haller; Nicolas Bouche; Bart Keymeulen; Marine R C Kraus; Daniel G Pipeleers
Journal:  Stem Cells Transl Med       Date:  2019-08-04       Impact factor: 6.940

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.